OmniAb, Inc. (NASDAQ:OABI – Get Rating) shares shot up 3.4% during mid-day trading on Wednesday . The company traded as high as $3.68 and last traded at $3.68. 1,021,565 shares changed hands during mid-day trading, an increase of 57% from the average session volume of 650,293 shares. The stock had previously closed at $3.56.
Wall Street Analysts Forecast Growth
A number of brokerages have issued reports on OABI. Stifel Nicolaus began coverage on OmniAb in a report on Monday, November 28th. They issued a “buy” rating and a $12.00 target price for the company. Cowen began coverage on OmniAb in a report on Wednesday, February 22nd. They issued an “outperform” rating and a $10.00 target price for the company. Cowen began coverage on OmniAb in a report on Wednesday, February 22nd. They issued an “outperform” rating and a $10.00 target price for the company. Credit Suisse Group began coverage on OmniAb in a report on Friday, December 16th. They issued an “outperform” rating and a $13.00 target price for the company. Finally, SVB Leerink began coverage on OmniAb in a report on Tuesday, November 29th. They issued an “outperform” rating and a $6.00 target price for the company. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, OmniAb currently has a consensus rating of “Buy” and an average price target of $10.29.
OmniAb Price Performance
The company’s 50-day moving average price is $3.87.
About OmniAb
OmniAb, Inc, a biotechnology company, provides therapeutic antibody discovery technologies in the United States. The company's discovery platform provides industry partners access to the diverse antibody repertoires and screening technologies to enable discovery of next-generation therapeutics. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates.
Featured Articles
- Get a free copy of the StockNews.com research report on OmniAb (OABI)
- Meta Platforms: Efficiency Gains Momentum, Stock Accelerates
- Pfizer’s Latest Acquisition Strengthens the Case for PFE Stock
- SentinelOne: Reversal In-Play For Cybersecurity Stocks
- Is Sportradar Group A Growth Stock To Bet On In 2023?
- Strong Guidance says Boeing is Ready for Takeoff
Receive News & Ratings for OmniAb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OmniAb and related companies with MarketBeat.com's FREE daily email newsletter.
